MARKET

MACK

MACK

Merrimack Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.35
-0.01
-0.16%
Opening 13:16 06/22 EDT
OPEN
6.35
PREV CLOSE
6.36
HIGH
6.45
LOW
6.35
VOLUME
4.78K
TURNOVER
--
52 WEEK HIGH
9.45
52 WEEK LOW
3.070
MARKET CAP
85.16M
P/E (TTM)
-21.3877
1D
5D
1M
3M
1Y
5Y
Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Can Afford To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Simply Wall St. · 06/08 09:31
Elevation Oncology Files for $100M IPO
Benzinga · 06/07 18:10
180 Life Sciences Shares Rise 18% After Naming 2 Directors
By Chris Wack 180 Life Sciences Corp. shares rose 18% to $9.37 after the company said it named Russell Ray and Teresa DeLuca to its board of directors,...
marketwatch.com · 05/28 14:10
180 Life Sciences Corp. Announces the Appointment of Russell T. Ray, MBA and Teresa DeLuca MD, MBA to Board of Directors
180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has ...
GlobeNewswire · 05/28 12:00
Receptor Tyrosine Protein Kinase ERBB 3 Market Industry Growth,Forecast, Analysis,Manufacturers, Regions, Types and Applications 2021-2028 By Ameco Research
Comserve · 05/07 08:15
10-Q: MERRIMACK PHARMACEUTICALS INC
(EDGAR Online via COMTEX) -- Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations. The following discussion of our...
Edgar Online - (EDG = 10Q, 10K) · 05/06 20:52
Global HER2 Positive Breast Cancer Market 2021 with (COVID-19) Impact Analysis, Product Type, Application, Key Manufacturers, Regions and Forecast to 2026
Apr 30, 2021 (Market Insight Reports) -- HER2 Positive Breast Cancer market report provides a comprehensive analysis of the business models, key market...
Market Insight Reports · 04/30 11:18
Global Receptor Tyrosine Protein Kinase ERBB 3 Market Analysis 2016-2020 and Forecast 2021-2026
Apr 17, 2021 (Heraldkeepers) -- Product Type Coverage (Market Size & Forecast, Major Company of Product Type...
Heraldkeepers · 04/17 08:02
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MACK. Analyze the recent business situations of Merrimack Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MACK stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 69
Institutional Holdings: 9.22M
% Owned: 68.72%
Shares Outstanding: 13.41M
TypeInstitutionsShares
Increased
17
192.54K
New
8
52.00K
Decreased
5
287.97K
Sold Out
3
66
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.48%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Chairman/President/Treasurer/Director
Gary Crocker
Independent Director
Eric Andersen
Independent Director
Noah Levy
Controller
John Green
Independent Director
Ulrik Nielsen
Independent Director
Russell Ray
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 0.5007
12/13/2019
07/25/2019
Dividend USD 0
09/06/2019
07/25/2019
Special Dividend USD 1.5
09/06/2019
04/04/2017
Dividend USD 0
05/30/2017
04/04/2017
Special Dividend USD 1.055209
05/30/2017
About MACK
Merrimack Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing novel treatments for cancer by targeting biomarker-defined cancers. Its clinical programs include MM-121 (seribantumab), MM-141 (istiratumab) and MM-310. MM-121 is a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1, or IGF-1, receptor and ErbB3 (HER3) cell surface receptor. MM-310 is an antibody-directed nanotherapeutic that targets the ephrin receptor A2, or EphA2, receptor and contains a novel prodrug of the highly potent chemotherapy docetaxel. The Company’s preclinical programs include MM-161, ATRi, BCL2/BCLxl, TRAIL, Immuno-oncology and STIMULI.

Webull offers kinds of Merrimack Pharmaceuticals Inc stock information, including NASDAQ:MACK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MACK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MACK stock methods without spending real money on the virtual paper trading platform.